Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapy
European Journal of Cancer2016Vol. 60, pp. 210–225
Citations Over TimeTop 1% of 2016 papers
Lisa Zimmer, Simone M. Goldinger, Lars Hofmann, Carmen Loquai, Selma Ugurel, Ioannis Thomas, Maria Isabel Schmidgen, Ralf Gutzmer, Jochen Utikal, Daniela Göppner, Jessica C. Hassel, Friedegund Meier, Julia K. Tietze, Andrea Forschner, Carsten Weishaupt, Martin Leverkus, R.U. Wahl, Ursula M. Dietrich, Claus Garbe, Michael Constantin Kirchberger, Thomas Eigentler, Carola Berking, Anja Gesierich, Angela M. Krackhardt, Dirk Schadendorf, Gerold Schuler, Reinhard Dummer, Lucie Heinzerling
Related Papers
- → Prolonged Benefit from Ipilimumab Correlates with Improved Outcomes from Subsequent Pembrolizumab(2016)21 cited
- → Japanese real‐world study of sequential nivolumab and ipilimumab treament in melanoma(2019)17 cited
- → Utility Values Across Lines of Therapy in Immuno-Oncology Treatments: An Example from Advanced Melanoma(2017)
- → The efficacy and safety of combined immune checkpoint inhibitors (nivolumab plus ipilimumab): a systematic review and meta-analysis(2020)
- → Combined effect of ipilimumab and nivolumab improves oncology endpoints in metastatic melanoma patients(2023)